Approval of Sarepta DMD gene therapy revives questions on FDA interactions with companies, patient advocates

The approval of Sarepta’s gene therapy for Duchenne muscular dystrophy has revived longstanding questions about non-public communications between FDA officials and companies that have pending approval applications, and about interactions between agency officials and patient advocacy organizations that are funded by companies with products under review.

The issues are complex. ...